Literature DB >> 25465229

Placental profiling of UGT1A enzyme expression and activity and interactions with preeclampsia at term.

Abby C Collier1,2, Audrey D Thévenon3, William Goh4, Mark Hiraoka4, Claire E Kendal-Wright4,5.   

Abstract

Placental UDP-glucuronosyltransferase (UGT) enzymes have critical roles in hormone, nutrient, chemical balance and fetal exposure during pregnancy. Placental UGT1A isoforms were profiled and differences between preeclamptic (PE) and non-PE placental UGT expression determined. In third trimester villous placenta, UGT1A1, 1A4, 1A6 and 1A9 were expressed and active in all specimens (n = 10), but UGT1A3, 1A5, 1A7, 1A8 and 1A10 were absent. The UGT1A activities were comparable to human liver microsomes per milligram, but placental microsome yields were only 2 % of liver (1 mg/g of tissue vs. 45 mg/g of tissue). For successful PCR, placental collection and processing within 60 min from delivery, including DNAse and ≥300 ng of RNA in reverse transcription were essential and snap freezing in liquid nitrogen immediately was the best preservation method. Although UGT1A6 mRNA was lower in PE (P < 0.001), there were no other significant effects on UGT mRNA, protein or activities. A more comprehensive tissue sample set is required for confirmation of PE interactions with UGT. Placental UGT1A enzyme expression patterns are similar to the liver and a detoxicative role for placental UGT1A is inferred.

Entities:  

Keywords:  Developmental pharmacology; Glucuronidation; Obstetrics; Phase II metabolism

Mesh:

Substances:

Year:  2014        PMID: 25465229      PMCID: PMC4536191          DOI: 10.1007/s13318-014-0243-4

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  53 in total

1.  Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs.

Authors:  Ryan G Snodgrass; Abby C Collier; Amy E Coon; Chris A Pritsos
Journal:  J Biol Chem       Date:  2010-04-23       Impact factor: 5.157

Review 2.  An update on the dietary ligands of the AhR.

Authors:  Hitoshi Ashida; Shin Nishiumi; Itsuko Fukuda
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-11       Impact factor: 4.481

3.  Assisted reproduction technologies impair placental steroid metabolism.

Authors:  Abby C Collier; Shogo J Miyagi; Yasuhiro Yamauchi; Monika A Ward
Journal:  J Steroid Biochem Mol Biol       Date:  2009-05-03       Impact factor: 4.292

4.  Mechanism of gender-divergent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney.

Authors:  David B Buckley; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2009-01-08       Impact factor: 3.922

5.  UGT3A: novel UDP-glycosyltransferases of the UGT superfamily.

Authors:  Robyn Meech; Peter I Mackenzie
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

6.  Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers.

Authors:  Takeshi Izukawa; Miki Nakajima; Ryoichi Fujiwara; Hiroyuki Yamanaka; Tatsuki Fukami; Masataka Takamiya; Yasuhiro Aoki; Shin-ichi Ikushiro; Toshiyuki Sakaki; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2009-05-13       Impact factor: 3.922

7.  The major chemical-detoxifying system of UDP-glucuronosyltransferases requires regulated phosphorylation supported by protein kinase C.

Authors:  Nikhil K Basu; Labanyamoy Kole; Mousumi Basu; Kushal Chakraborty; Partha S Mitra; Ida S Owens
Journal:  J Biol Chem       Date:  2008-06-13       Impact factor: 5.157

8.  Differential expression and distribution of placental glutathione peroxidases 1, 3 and 4 in normal and preeclamptic pregnancy.

Authors:  H D Mistry; L O Kurlak; P J Williams; M M Ramsay; M E Symonds; F Broughton Pipkin
Journal:  Placenta       Date:  2010-03-19       Impact factor: 3.481

9.  Does rapid metabolism ensure negligible risk from bisphenol A?

Authors:  Gary Ginsberg; Deborah C Rice
Journal:  Environ Health Perspect       Date:  2009-07-14       Impact factor: 9.031

10.  Time course analysis of RNA stability in human placenta.

Authors:  Isabelle Fajardy; Emmanuelle Moitrot; Anne Vambergue; Maryse Vandersippe-Millot; Philippe Deruelle; Jean Rousseaux
Journal:  BMC Mol Biol       Date:  2009-03-10       Impact factor: 2.946

View more
  5 in total

1.  Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

Review 2.  Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.

Authors:  Ankit Balhara; Aditya R Kumar; Jashvant D Unadkat
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

Review 3.  Placental control of drug delivery.

Authors:  Sanaalarab Al-Enazy; Shariq Ali; Norah Albekairi; Marwa El-Tawil; Erik Rytting
Journal:  Adv Drug Deliv Rev       Date:  2016-08-12       Impact factor: 15.470

4.  Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.

Authors:  Jolien J M Freriksen; Stein Schalkwijk; Angela P Colbers; Khaled Abduljalil; Frans G M Russel; David M Burger; Rick Greupink
Journal:  Clin Pharmacol Ther       Date:  2020-01-24       Impact factor: 6.875

5.  Transfer and Metabolism of the Xenoestrogen Zearalenone in Human Perfused Placenta.

Authors:  Benedikt Warth; Karin Preindl; Pius Manser; Peter Wick; Doris Marko; Tina Buerki-Thurnherr
Journal:  Environ Health Perspect       Date:  2019-10-09       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.